- Policy
- A new drug preferential law will be promoted
- by Lee, Jeong-Hwan Oct 15, 2021 05:57am
- The MOHW announced that it will start enacting subordinate laws to substantially implement and secure the effectiveness of the "clause for preferential treatment of new domestic drugs" developed by innovative pharmaceutical companies under the Special Act on the Pharmaceutical Industry. The "upper limit price preferential treatment of drug
- Company
- ‘Ibrance’ opens new horizon as the lead CDK4/6 inhibitor
- by Oct 14, 2021 05:38am
- The breast cancer treatment ‘Ibrance (palbociclib)’ was what established Pfizer Korea as the ‘anticancer drug power’ in Korea. The company had other excellent anticancer drugs such as ‘Xalkori,’ and ‘Sutene,’ but none had received as much spotlight as Ibrance. As the ‘first CDK4/6 inhibitor,’ and ‘the first new breast cancer drug i
- Policy
- No need to extend the benefit period of Keytruda
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- The MOHW said there is little need to extend the benefit period of Keytruda, an immuno-cancer drug, for patients who are effective in secondary treatment of non-small cell lung cancer by more than two years. This is because the clinical period of Keytruda was designed to be two years, and related societies such as the Korean Association fo
- Policy
- Poor ‘Benefit Adequacy Assessment' in controversy
- by Lee, Jeong-Hwan Oct 14, 2021 05:38am
- A bill to specify the basic definition of the Insurance Benefit Adequacy Assessment and stipulate the submission period for its data for assessment is being promoted. On the 13th, the National Assembly member Jong-Sik Heo announced that he had presented a bill for the partial amendment of the National Health Insurance Act that contained t
- Company
- Korea Otsuka Pharma’s Hyangnam Plant rises as a global hub
- by Nho, Byung Chul Oct 14, 2021 05:38am
- Korea Otsuka Pharmaceutical, which is soon to face its 40th anniversary in Korea, is receiving attention with its Hyangnam Plant rising as a forward base for global exports and production. Korea Otsuka Pharmaceutical is a global total healthcare enterprise that covers a wide range of businesses from clinical research, R&D, manufacturing,
- Policy
- # of COVID-19 confirmed medical staff doubled in 3 months
- by Lee, Jeong-Hwan Oct 14, 2021 05:37am
- Among domestic medical personnel, the cumulative number of confirmed cases of COVID-19 has more than doubled compared to three months ago. Out of a total of 321,352 COVID-19 confirmed patients as of 0 o'clock on the 5th, 5,444 were medical personnel or medical institution workers. On the 12th, Choi Yeon-sook of the People Party made this anno
- Policy
- Suspicions of preferential tx for SK Bioscience & Celltrion
- by Lee, Tak-Sun Oct 14, 2021 05:37am
- Suspicions have been raised during a parliamentary audit, led by opposition lawmakers, that the MFDS may have provided preferential treatment to the company for domestic COVID-19 drugs. Kim Kang-rip, head of the MFDS, dismissed the suspicion, saying he approved it based on evidence. Fentanyl Patch, a drug pain reliever, is being used by t
- Company
- Tabrecta/ Rybrevant are expected to enter the market
- by Eo, Yun-Ho Oct 13, 2021 05:47am
- Two types of anticancer drugs targeting MET gene mutations are expected to enter the domestic market. According to related industries, Novartis Korea and Janssen Korea submitted applications to the MFDS for approval of the new anticancer drugs Tabrecta (Capmatinib) and Rybrevant (Amivantamab), respectively, and are currently undergoing screen
- Policy
- MFDS will quickly & thoroughly verify Merck's COVID-19 tx
- by Lee, Tak-Sun Oct 13, 2021 05:46am
- It was pointed out that Merck's oral treatment, which is considered a COVID-19 game changer, should be quickly introduced in Korea. Kang Ki-yoon, a member of the People Power Party, said in a parliamentary audit of the MFDS held at the National Assembly on the 8th, "Oral treatments are needed during the With Corona," stressing, "Not only
- Policy
- ‘Skilarence’ may be reimbursed if it accepts PBAC's price
- by Lee, Hye-Kyung Oct 13, 2021 05:46am
- Kolon Pharma’s plaque psoriasis treatment 'Skilarence Enteric Coated Tab. (Dimethyl fumarate)' will be reimbursed if the company accepts a price lower than the price assessed by the Pharmaceutical Benefit Assessment Committee. On the 8th, the National Health Insurance Service (President Sun-min Kim) disclosed the deliberation results on the
